SCHEMBL4112101

SCHEMBL4112101

COC(=O)c1ccc(NC(=O)Nc2ccc(C(C)=O)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.74
ALDH1A1 P00352 2/20 0.74
MEN1 O00255 11/20 0.72
KMT2A Q03164 11/20 0.72
NPC1 O15118 8/20 0.72
RAB9A P51151 7/20 0.72
HTT P42858 3/20 0.72
KDM4E B2RXH2 2/20 0.72
MAPK1 P28482 2/20 0.72
SMN1; SMN2 Q16637 4/20 0.68
TAAR1 Q96RJ0 1/20 0.68
NLRP1 Q9C000 1/20 0.66
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
CASP3 P42574 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
CA12 O43570 2/20 0.58
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3633396 0.88 NPC1 (0.84) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL588230 0.86 CA1 (0.67) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4113098 0.85 MAPT (1.00) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4118099 0.85 ALDH1A1 (0.75) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4112603 0.85 MEN1 (0.75) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4111942 0.84 MAPT (1.00) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL28614998 0.84 MAPT (1.00) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL20815531 0.84 MAPT (0.72) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4106651 0.84 RAB9A (0.79) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4113542 0.84 MAPT (0.72) MAPTALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885ALDH1A1 994/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.